Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count

Journal of Medical Virology

Volumn 86, Issue 1, 2014, Pages 97-101

  Milazzo, Laura ^a   Ebranati, Erika ^a   Cattaneo, Dario ^a   Gabanelli, Elena ^a   Lai, Alessia ^a   Zehender, Gianguglielmo ^a   Gervasoni, Cristina ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HBV reactivation; HIV infection; Viral escape

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LIVER ENZYME; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; VITRONECTIN;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV TEST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; IMMUNOASSAY; LABORATORY TEST; PHYLOGENY; RECURRENT INFECTION; TREATMENT DURATION; VIRUS ENTRY; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS STRAIN;

HEPATITIS B VIRUS;

HBV REACTIVATION; HIV INFECTION; VIRAL ESCAPE;

CD4 LYMPHOCYTE COUNT; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; VIRUS ACTIVATION;

EID: 84887822666     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23721     Document Type: Article

References (16)

1. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
2. Cheung WI, Chan HL, Leung VK, Tse CH, Fung K, Lin SY, Wong A, Wong VW, Chau TN. 2010. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol 47:193-195.
3. Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C, Cramp ME. 2006. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS 17:67-69.
4. Costantini A, Marinelli K, Biagioni G, Monachetti A, Ferreri ML, Butini L, Montroni M, Manzin A, Bagnarelli P. 2011. Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infect Dis 11:310.
5. De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, Bernini F, Ebranati E, Cargnel A, Bruno R, Galli M, Zehender G. 2007. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology 365:113-124.
6. González de Requena D, Blanco F, Garcia-Benayas T, Jiménez-Nácher I, González-Lahoz J, Soriano V. 2003. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 17:443-445.
7. Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A. 2003. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 33:594-600.
8. Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, Trautwein C, Deppe H, Schulz TF, Heim A, Tacke F. 2008. Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 198:1620-1624.
9. Locarnini S, Zoulim F. 2010. Molecular genetics of HBV infection. Antivir Ther 15(Suppl 3):3-14.
10. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Günther S. 2001. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 32:144-148.
11. Martel N, Cotte L, Trabaud MA, Trepo C, Zoulim F, Gomes SA, Kay A. 2012. Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape. J Infect Dis 205:1757-1761.
12. Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A. 2005. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 56:790-792.
13. Sulkowski MS. 2004. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infec Dis 38:S90-S97.
14. Waite J, Gilson RJ, Weller IV, Lacey CJ, Hambling MH, Hawkins A, Briggs M, Tedder RS. 1988. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 2:443-448.
15. Wu C, Deng W, Deng L, Cao L, Qin B, Li S, Wang Y, Pei R, Yang D, Lu M, Chen X. 2012. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol 86:4658-4669.
16. Zuckerman JN, Zuckerman AJ. 2000. Current topics in hepatitis B. J Infect 41:130-136.